Hematologic Malignancies
Fondazione Tettamanti focuses on clinical research in B-cell precursor acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, and chronic lymphocytic leukemia, with activity centered in Monza, Italy.
- Relapsed/refractory leukemia
- B-cell lymphoma
- Chronic lymphocytic leukemia
The sponsored studies are concentrated on blood cancers with unmet treatment needs, particularly in patients requiring novel cellular therapies.
CARCIK-CD19 Cellular Therapy
The sponsor supports research on CARCIK-CD19, an CD19-targeted cellular immunotherapy evaluated across pediatric and adult populations.
- CD19-directed therapy
- Allogeneic CARCIK cells
- HLA haploidentical familial cells
Clinical interest includes both autologous and allogeneic cellular approaches for hematologic cancer treatment.
Minimal Residual Disease-Guided Treatment
Research activity includes strategies guided by residual disease assessment in acute lymphoblastic leukemia, reflecting interest in disease monitoring linked to therapeutic decision-making.
- Residual disease
- Response assessment
- Relapse-focused care
This area connects diagnostic refinement with treatment selection in leukemia care.
Clinical Efficacy in B-Cell Cancers
The funded trials emphasize overall response and treatment benefit in B-cell malignancies, including both lymphoma and leukemia settings.
- Overall response rate
- Treatment durability
- Patient response evaluation
These studies support clinical development of immune-based oncology approaches for difficult-to-treat blood cancers.
